Investment
Features
FeesSafety
Academy
More
Pluang+

First patient treated in clinical trial of IBA's innovative ConformalFLASH® proton therapy for head and neck cancer.

Market News
21 Oct 2026
Iba (Ion Beam Applications S.A.)
View Source
Bullish
First patient treated in clinical trial of IBA's innovative ConformalFLASH® proton therapy for head and neck cancer.

IBA has treated the first patient in the C-FLASH-01 clinical trial, the first human study testing ConformalFLASH® proton therapy. This trial, conducted at Penn Medicine with FDA approval, explores the feasibility of using ultra-high dose rate proton therapy for re-irradiation in head and neck cancer patients. The treatment combines precise proton beam targeting with FLASH radiotherapy technology, potentially improving cancer treatment outcomes. The trial's results will help guide future development and clinical use of this advanced therapy.

The first patient treated in the C-FLASH-01 ConformalFLASH® clinical trial offers context for health-sector market activity. For readers following health stocks, 133 of 150 priced US health-sector stocks on Pluang rose while 17 fell. Notable movers include SYRE at USD 91.75 (+8.30%), NUVB at USD 4.84 (+8.04%), and TDOC at USD 6.19 (+8.03%). These figures are as of Oct 21, 2026 09:41 WIB.

More News

WISeQey lists on Nasdaq, aims to build secure AI and satellite platform for the Intelligence Age

WISeQey lists on Nasdaq, aims to build secure AI and satellite platform for the Intelligence Age

WISeQey Corp. completed its redomiciliation and began trading on Nasdaq and the SIX Swiss Exchange, marking a new phase focused on integrating its quantum cybersecurity, digital identity, and space IoT technologies. Its subsidiary WISeSat.Space also ...

Market News
Bullish
13 minutes ago
IBA treats first patient in clinical trial for innovative ConformalFLASH® proton therapy

IBA treats first patient in clinical trial for innovative ConformalFLASH® proton therapy

IBA has treated the first patient in the C-FLASH-01 clinical trial, testing its ConformalFLASH® proton therapy for head and neck cancer re-irradiation. This trial, led by Penn Medicine and approved by the FDA, explores ultra-high dose rate proton the...

Market News
Bullish
13 minutes ago
Sika to acquire Resonac's adhesives business, boosting growth in Asian automotive markets.

Sika to acquire Resonac's adhesives business, boosting growth in Asian automotive markets.

Sika AG has agreed to acquire the adhesives business of Japan's Resonac Corporation, which serves automotive customers across Asia. This acquisition will expand Sika's access to key Japanese automotive OEM suppliers and broaden its product offerings,...

Company Fundamentals
Bullish
13 minutes ago
Hudbay and Mitsubishi approve Copper World project, aiming for U.S. copper mine production by 2029

Hudbay and Mitsubishi approve Copper World project, aiming for U.S. copper mine production by 2029

Hudbay and Mitsubishi have approved the construction of the Copper World project, a major new copper mine in the U.S. This project is significant as it advances the development of a key resource mine, with production expected to begin in 2029. The ap...

Market News
Bullish
13 minutes ago
Sika acquires Resonac's adhesive division to boost growth in Asian automotive markets.

Sika acquires Resonac's adhesive division to boost growth in Asian automotive markets.

Sika AG has agreed to acquire the adhesive division of Japan's Resonac Corporation, which specializes in adhesive technologies primarily for automotive customers in Asia. This acquisition enhances Sika's market access to key Japanese automotive suppl...

Company Fundamentals
Bullish
13 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App